Hekker, Marleen D.
Platteel, Tamara N.
Venekamp, Roderick P.
Top, Janetta
Geerlings, Suzanne E.
Schultsz, Constance
de Vos, Marjon G.J.
van de Wijgert, Janneke H. H. M.
Funding for this research was provided by:
The Dutch Research Council (OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088, OCENW.XL21.XL21.088)
Article History
Received: 13 June 2025
Accepted: 17 June 2025
First Online: 1 July 2025
Declarations
:
: The UTIr cohort study is conducted in accordance with the Declaration of Helsinki (2013 version) and the Dutch Medical Research Involving Human Subjects Act (Wet Medisch Onderzoek, WMO). The study protocol and other study related documents were reviewed and approved by the Medical Research Ethics Committee NedMec (dossier number 23-165/A; NL84448.041.23) and each participant provides written informed consent.
: Not applicable.
: SG declares to be on the CureVac advisory board for a mRNA vaccine against uropathogenic E. coli. The other authors declare no competing interests.